<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360915</url>
  </required_header>
  <id_info>
    <org_study_id>ASK-LC-120067-Ib</org_study_id>
    <nct_id>NCT04360915</nct_id>
  </id_info>
  <brief_title>Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects</brief_title>
  <official_title>Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Aosaikang Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Aosaikang Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetic characteristics of ASK120067 and CCB4580030 after the single&#xD;
      oral administration of ASK120067 in fast and after a high-fat meal in healthy Chinese&#xD;
      subjects, and to evaluate the effect of food on the bioavailability of ASK120067.To evaluate&#xD;
      the safety of ASK120067 tablets administered orally in fast and fed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)</time_frame>
    <description>Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)</time_frame>
    <description>Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out area under the plasma concentration-time curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)</time_frame>
    <description>Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out time to reach maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)</time_frame>
    <description>Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out apparent end elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)</time_frame>
    <description>Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)</time_frame>
    <description>Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Î»z</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)</time_frame>
    <description>Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out apparent terminal elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Treatment-Emergent Adverse Events</measure>
    <time_frame>Adverse events will be collected from baseline until 12 days after the administration and the follow-up period</time_frame>
    <description>Assessed by number and severity of adverse events as recorded on the case report form.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Locally Advanced or Metastatic NSCLC</condition>
  <arm_group>
    <arm_group_label>ASK120067 in fast condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take ASK120067 tablets orally once in the first day at 160mg in fast condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASK120067 in fed condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take ASK120067 tablets orally once in the first day at 160mg in fed condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASK120067</intervention_name>
    <description>Take ASK120067 tablets orally in first day at 160 mg in fast condition.</description>
    <arm_group_label>ASK120067 in fast condition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ASK120067 in fed condition</intervention_name>
    <description>Take ASK120067 tablets orally in first day at 160 mg in fed condition.</description>
    <arm_group_label>ASK120067 in fed condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Healthy subjects aged 18 or above and 45 or below, male and female;&#xD;
&#xD;
          -  2) The weight of male subjects shall not be less than 50 kg, and that of female&#xD;
             subjects shall not be less than 45 kg.Body mass index (BMI) = weight (kg)/height2&#xD;
             (m2), BMI = Within the range of 19.0~26.0 (including the critical value);&#xD;
&#xD;
          -  3) Normal or abnormal physical examination (physical examination, vital signs,&#xD;
             laboratory examination, 12-lead electrocardiogram, frontal and lateral chest&#xD;
             radiographs, etc.) during the screening period has no clinical significance;&#xD;
&#xD;
          -  4) Subjects (including male subjects) are willing to have no pregnancy plan from the&#xD;
             screening date to 6 months after the last dose, and are willing to take effective&#xD;
             contraceptive measures;&#xD;
&#xD;
          -  5) Subjects should sign the informed consent before the test, fully understand the&#xD;
             test content, process and possible adverse reactions, have good communication with&#xD;
             researchers and complete the test according to the test plan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) patients with clinical significance who are abnormal by comprehensive physical&#xD;
             examination, vital signs examination, routine laboratory examination (blood routine,&#xD;
             urine routine, blood biochemistry, coagulation function), 12-lead electrocardiogram,&#xD;
             and positive and lateral chest radiographs;&#xD;
&#xD;
          -  2) HBSAg HCVAb HIVAb, treponema palliatum antibody and other test results were&#xD;
             positive;&#xD;
&#xD;
          -  3) QTc interphase abnormality (QTc&gt;450ms) with clinical significance;&#xD;
&#xD;
          -  4) participated in the drug clinical trial within 3 months before the trial;&#xD;
&#xD;
          -  5) taking any medication 14 days before the trial;&#xD;
&#xD;
          -  6) surgical resection history, such as: hepatectomy, nephrectomy, digestive organ&#xD;
             (gallbladder) resection;&#xD;
&#xD;
          -  7) history of tuberculosis;&#xD;
&#xD;
          -  8) past history of deep vein thrombosis/other thromboembolic events, abnormal&#xD;
             coagulation factors, thrombocytopenia, or abnormal platelet function;&#xD;
&#xD;
          -  9) previous history of interstitial lung disease (ILD), drug-induced ILD, radioactive&#xD;
             pneumonia requiring steroid treatment, or clinically active ILD with evidence;&#xD;
&#xD;
          -  10) allergic or hypersensitive to ASK120067 experimental active ingredients or&#xD;
             inactive excipients, drugs with similar chemical structure to the experimental drugs&#xD;
             or drugs with the same target, allergic to two or more drugs and food;&#xD;
&#xD;
          -  11) there are swallowing difficulties or gastrointestinal diseases affecting drug&#xD;
             absorption;&#xD;
&#xD;
          -  12) have any disease that increases the risk of bleeding, such as acute gastritis or&#xD;
             gastric and duodenal ulcers;&#xD;
&#xD;
          -  13) habitual constipation or diarrhea;&#xD;
&#xD;
          -  14) heavy drinking and/or a history of excessive drinking (14 units of alcohol per&#xD;
             week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);&#xD;
&#xD;
          -  15) alcohol breath test &gt; 0.0mg /100mL;&#xD;
&#xD;
          -  16) drug abuse screening positive;&#xD;
&#xD;
          -  17) smoking history, smoking more than 5 cigarettes per day in the first 3 months of&#xD;
             the screening period or habitual use of nicotine-containing products, and unable to&#xD;
             quit during the trial;&#xD;
&#xD;
          -  18) those with positive urine nicotine detection results at the screening stage;&#xD;
&#xD;
          -  19) having a history of blood or needle sickness;&#xD;
&#xD;
          -  20) habitual consumption and consumption of special diet (including grapefruit juice,&#xD;
             star fruit, pitaya fruit, etc.) within 7 days before the test, or the presence of&#xD;
             other factors affecting drug absorption, distribution, metabolism, excretion, etc.;&#xD;
&#xD;
          -  21) blood donation or massive blood loss (&gt; 400 mL) within 3 months prior to the&#xD;
             trial;&#xD;
&#xD;
          -  22) an acute illness or accident occurs during the screening period;&#xD;
&#xD;
          -  23) the female subjects were lactating, or the pregnancy test results were positive,&#xD;
             or they had unprotected sex within 2 weeks before the screening date;&#xD;
&#xD;
          -  24) there are other conditions that the researcher thinks are not suitable for&#xD;
             inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zourong Ruan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

